Discovery of specific inhibitors for intestinal E. coli β -glucuronidase through in silico virtual screening

Scientific World Journal

Volumn 2015, Issue , 2015, Pages

  Cheng, Ta Chun ^a   Chuang, Kuo Hsiang ^a   Roffler, Steve R ^b   Cheng, Kai Wen ^c   Leu, Yu Lin ^d   Chuang, Chih Hung ^e   Huang, Chien Chaio ^e   Kao, Chien Han ^e   Hsieh, Yuan Chin ^e   Chang, Long Sen ^c   Cheng, Tian Lu ^a,e   Chen, Chien Shu ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; BETA GLUCURONIDASE; BETA GLUCURONIDASE INHIBITOR; GLYCOSIDASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ESCHERICHIA COLI PROTEIN;

ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ESCHERICHIA COLI; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IC50; MOLECULAR DOCKING; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; HUMAN; INTESTINE FLORA; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

BACTERIA (MICROORGANISMS);

COMPUTER SIMULATION; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GASTROINTESTINAL MICROBIOME; GLUCURONIDASE; HUMANS; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, SECONDARY;

EID: 84925763792     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2015/740815     Document Type: Article

References (37)

1. G. M. Nelson, A. E. Swank, L. R. Brooks, K. C. Bailey, and S. E. George, "Metabolism, microflora effects, and genotoxicity in haloacetic acid-treated cultures of rat cecal microbiota," Toxicological Sciences, vol. 60, no. 2, pp. 232-241, 2001.
2. I. Rowland, "The influence of the gut microflora on food toxicity," Proceedings of the Nutrition Society, vol. 40, no. 1, pp. 67-74, 1981.
3. C. Humblot, M. Murkovic, L. Rigottier-Gois et al., "β-glucuronidase in human intestinal microbiota is necessary for the colonic genotoxicity of the food-borne carcinogen 2-amino-3-methylimidazo[4,5-f]quinoline in rats," Carcinogenesis, vol. 28, no. 11, pp. 2419-2425, 2007.
4. A. Rowland, J. O. Miners, and P. I. Mackenzie, "The UDPglucuronosyltransferases: their role in drug metabolism and detoxification," International Journal of Biochemistry and Cell Biology, vol. 45, no. 6, pp. 1121-1132, 2013.
5. K. Takasuna, T. Hagiwara, K. Watanabe et al., "Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea," Cancer Chemotherapy and Pharmacology, vol. 58, no. 4, pp. 494-503, 2006.
6. T. Chihara, K. Shimpo, T. Kaneko et al., "Inhibition of 1, 2-dimethylhydrazine-induced mucin-depleted foci and O6-methylguanine DNA adducts in the rat colorectum by boiled garlic powder," Asian Pacific Journal of Cancer Prevention, vol. 11, no. 5, pp. 1301-1304, 2010.
7. P. M. Kim and P. G. Wells, "Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene," Cancer Research, vol. 56, no. 7, pp. 1526-1532, 1996.
8. M. Kim, S. Miyamoto, S. Sugie et al., "A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice," In Vivo, vol. 22, no. 5, pp. 557-564, 2008.
9. K. R. Kaderlik, R. F. Minchin, G. J. Mulder et al., "Metabolic activation pathway for the formation of DNA adducts of the carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in rat extrahepatic tissues," Carcinogenesis, vol. 15, no. 8, pp. 1703-1709, 1994.
10. N. Nalini, V. Manju, and V. P. Menon, "Effect of coconut cake on the bacterial enzyme activity in 1,2-dimethyl hydrazine induced colon cancer," Clinica Chimica Acta, vol. 342, no. 1-2, pp. 203-210, 2004.
11. N. Nalini, K. Sabitha, P. Viswanathan, and V. P. Menon, "Influence of spices on the bacterial (enzyme) activity in experimental colon cancer," Journal of Ethnopharmacology, vol. 62, no. 1, pp. 15-24, 1998.
12. A. Likhachev, V. Anisimov, L. Paranova, and K. Pozharisski, "Effect of exogenous β-glucuronidase on the carcinogenicity of 1,2-dimethylhydrazine in rats: evidence that carcinogenic intermediates form conjugates and act through their subsequent enzymatic release," Carcinogenesis, vol. 6, no. 5, pp. 679-681, 1985.
13. S. N. Newaz, W. F. Fang, and H. W. Strobel, "Metabolism of the carcinogen 1,2-dimethylhydrazine by isolated human colon microsomes and human colon tumor cells in culture," Cancer, vol. 52, no. 5, pp. 794-798, 1983.
14. S. Wolter and N. Frank, "Metabolism of 1,2-dimethylhydrazine in isolated perfused rat liver," Chemico-Biological Interactions, vol. 42, no. 3, pp. 335-344, 1982.
15. K. Kobayashi, "Chemotherapy-induced diarrhea," Gan To Kagaku Ryoho, vol. 30, no. 6, pp. 765-771, 2003.
16. B. D. Wallace, H. Wang, K. T. Lane et al., "Alleviating cancer drug toxicity by inhibiting a bacterial enzyme," Science, vol. 330, no. 6005, pp. 831-835, 2010.
17. A. B. Roberts, B. D. Wallace, M. K. Venkatesh, S. Mani, and M. R. Redinbo, "Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity," Molecular Pharmacology, vol. 84, no. 2, pp. 208-217, 2013.
18. S. Cascinu, E. Bichisao, D. Amadori et al., "High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients," Supportive Care in Cancer, vol. 8, no. 1, pp. 65-67, 2000.
19. G. Dranitsaris, J. Maroun, and A. Shah, "Severe chemotherapyinduced diarrhea in patients with colorectal cancer: a cost of illness analysis," Supportive Care in Cancer, vol. 13,no. 5, pp. 318-324, 2005.
20. M. Fittkau, W. Voigt, H.-J. Holzhausen, and H.-J. Schmoll, "Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats," Journal of Cancer Research and Clinical Oncology, vol. 130, no. 7, pp. 388-394, 2004.
21. G. Constantopoulos, S. Rees, B. G. Cragg, J. A. Barranger, and R. O. Brady, "Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat," Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 6, pp. 3700-3704, 1980.
22. P. M. Gillett, R. A. Schreiber, G. P. Jevon et al., "Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly," Journal of Pediatric Gastroenterology and Nutrition, vol. 33, no. 2, pp. 216-220, 2001.
23. S. Ahmad, M. A. Hughes, L.-A. Yeh, and J. E. Scott, "Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors," Journal of Biomolecular Screening, vol. 17, no. 7, pp. 957-965, 2012.
24. R. Kong, T. Liu, X. Zhu et al., "Old drug new use-amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity," Clinical Cancer Research, vol. 20, no. 13, pp. 3521-3530, 2014.
25. I. D. Kuntz, "Structure-based strategies for drug design and discovery," Science, vol. 257, no. 5073, pp. 1078-1082, 1992.
26. E.C. Meng, B. K. Shoichet, and I. D. Kuntz, "Automateddocking with grid-based energy evaluation," Journal of Computational Chemistry, vol. 13, no. 4, pp. 505-524, 1992.
27. T.-L. Cheng, B.-M. Chen, L.-Y. Chan, P.-Y. Wu, J.-W. Chern, and S. R. Roffler, "Poly(ethylene glycol) modification of β-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs," Cancer Immunology Immunotherapy, vol. 44, no. 6, pp. 305-315, 1997.
28. G. Jones, P. Willett, R. C. Glen, A. R. Leach, and R. Taylor, "Development and validation of a genetic algorithm for flexible docking," Journal of Molecular Biology, vol. 267, no. 3, pp. 727-748, 1997.
29. N.C. Cohen, J.M. Blaney, C. Humblet, P. Gund, and D. C. Barry, "Molecular modeling software and methods for medicinal chemistry," Journal of Medicinal Chemistry, vol. 33, no. 3, pp. 883-894, 1990.
30. E. T. Maggio and K. Ramnarayan, "Recent developments in computational proteomics," Drug Discovery Today, vol. 6, no. 19, pp. 996-1004, 2001.
31. Y.-C. Su, K.-H. Chuang, Y.-M. Wang et al., "Gene expression imaging by enzymatic catalysis of a fluorescent probe via membrane-anchored β-glucuronidase," Gene Therapy, vol. 14, no. 7, pp. 565-574, 2007.
32. Y.-L. Leu, S. R. Roffler, and J.-W. Chern, "Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)," Journal ofMedicinal Chemistry, vol. 42, no. 18, pp. 3623-3628, 1999.
33. A. W. Wong, S. He, J. H. Grubb, W. S. Sly, and S. G. Withers, "Identification of Glu-540 as the catalytic nucleophile of human β-glucuronidase using electrospray mass spectrometry," The Journal of Biological Chemistry, vol. 273, no. 51, pp. 34057-34062, 1998.
34. T. Legigan, J. Clarhaut, B. Renoux et al., "Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin," Journal of Medicinal Chemistry, vol. 55, no. 9, pp. 4516-4520, 2012.
35. T.-C. Cheng, S. R. Roffler, S.-C. Tzou et al., "An activitybased near-infrared glucuronide trapping probe for imaging β-glucuronidase expression in deep tissues," Journal of the American Chemical Society, vol. 134, no. 6, pp. 3103-3110, 2012.
36. A. Stein, W. Voigt, and K. Jordan, "Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management," Therapeutic Advances in Medical Oncology, vol. 2, no. 1, pp. 51-63, 2010.
37. D.-H. Kim and Y.-H. Jin, "Intestinal bacterial β-glucuronidase activity of patients with colon cancer," Archives of Pharmacal Research, vol. 24, no. 6, pp. 564-567, 2001.